New understanding of the way anti-inflammatory drug works in people with rheumatoid arthritis

Researchers at the University College London (UCL) have discovered that the widely used anti-inflammatory drug HUMIRA, doesn’t just work by inhibiting its target protein, TNF, but also by enhancing a particular function of TNF in rheumatoid arthritis patients.

The study, which was published in The Journal of Experimental Medicine, may help explain the divergent efficacies of different TNF-targeting drugs.

TNF is an important inflammatory molecule produced by the immune system, and TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. One such inhibitor is the monoclonal anti-TNF antibody adalimumab, commonly marketed under the brand name HUMIRA.

Michael Ehrenstein and researchers from UCL previously found that treating rheumatoid arthritis patients with adalimumab increased the number of regulatory T cells capable of suppressing inflammation. It was presumed that this was because, in the absence of adalimumab, TNF blocks the development of these regulatory T cells. Interestingly, however, another TNF inhibitor, etanercept, doesn’t induce the formation of these inflammation-suppressing T cells in rheumatoid arthritis patients.

Ehrenstein and his colleague, Dao Xuan Nguyen, now report that, unlike etanercept, adalimumab actually enhances the ability of TNF to induce the formation of antiinflammatory T cells. In particular, the research team discovered that adalimumab increases the expression of TNF on the surface of patient monocytes and promotes the association of these TNF molecules with receptor proteins on the surface of regulatory T cells. This activates a signaling pathway that endows the T cells with the capacity to suppress inflammation.

Adalimumab may therefore block the proinflammatory functions of soluble TNF secreted by immune cells, while augmenting the activity of membrane-bound TNF that ultimately helps to resolve inflammation. “These results highlight how a treatment that targets a pivotal inflammatory cytokine not only preserves but actually boosts the pro-resolution forces driven by that pathway, thereby introducing a novel therapeutic paradigm,” Ehrenstein says.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.